Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ruxoprubart
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
NovelMed’s Ruxoprubart Shows Best-in-Class Results for PNH in Phase II Trial
Details : NM8074 (ruxoprubart), a human immunoglobulin, exhibits dual specificity, it blocks only the Alternative Pathway, dysregulated by the disease, and it binds Bb which has no binding to Factor B.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 19, 2025
Lead Product(s) : Ruxoprubart
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NM8074
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of NM8074 in Patients with Dermatomyositis (DM)
Details : NM8074 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatomyositis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 20, 2025
Lead Product(s) : NM8074
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ruxoprubart
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves NM8074 (ruxoprubart) IND for Dermatomyositis (DM)
Details : NM8074 (ruxoprubart) is an alternative pathway (AP) blocker anti-Bb antibody. It is being evaluated for the treatment of dermatomyositis .
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 24, 2025
Lead Product(s) : Ruxoprubart
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ruxoprubart
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
NovelMed IND Approval for NM8074, First Anti-Bb Blocker for IgA Nephropathy
Details : NM8074 (ruxoprubart) is an alternative pathway (AP) blocker anti-Bb antibody. It is being evaluated for the treatment of primary immunoglobulin A nephropathy.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : Ruxoprubart
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ruxoprubart
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Ruxoprubart Phase II Trial for ANCA Associated Vasculitis
Details : Ruxoprubart is a humanized monoclonal antibody to Bb, selectively blocking the initiation and propagation of the alternative pathway (AP). It is being investigated for ANCA Associated Vasculitis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 17, 2024
Lead Product(s) : Ruxoprubart
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NM8074
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)
Details : NM8074 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glomerulonephritis, IGA.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 12, 2024
Lead Product(s) : NM8074
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NM5072
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Awards Orphan Drug Designation to NM5072 for Paroxysmal Nocturnal Hemoglobinuria
Details : NM5072, an investigational orphan drug, selectively binds Properdin to block PNH RBC lysis, potentially treating PNH pathology.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 15, 2024
Lead Product(s) : NM5072
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ruxoprubart
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ruxoprubart Receives FDA Orphan Drug Designation for Paroxysmal Nocturnal Hemoglobinuria
Details : NM8074 (ruxoprubart) is an alternative pathway (AP) blocker anti-Bb antibody. It is being evaluated for the treatment of paroxysmal nocturnal hemoglobinuria.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 12, 2024
Lead Product(s) : Ruxoprubart
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NM8074
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NM8074 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
January 26, 2024
Lead Product(s) : NM8074
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ruxoprubart
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
USAN Approves Generic Name “Ruxoprubart” for NM8074, Targets Complement-Mediated Diseases
Details : NM8074 (ruxoprubart) is a novel Factor B binder, which is under phase 2 clinical development for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
January 08, 2024
Lead Product(s) : Ruxoprubart
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable